Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients. - Wikidata - awgldk - TriplyDB

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.

http://www.wikidata.org/entity/Q37091636

about

Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis.

P2860

Q47139593-8A322B7D-25F8-46DD-BEAD-89AB94852999

P2860

Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients.

http://www.wikidata.org/entity/Q37091636

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@en

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@nl

type

label

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@en

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@nl

prefLabel

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@en

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@nl

P1433

Q37091636-D4031362-6759-4C49-B3B8-5027292D3C75

P1476

Q37091636-59513A36-7D54-451A-9A6C-DB64DD1BBF0F

P2093

Q37091636-29DF1CFD-E3E8-4E71-8183-AB4AB93DAEBD

Q37091636-348E3010-A0D1-411B-BBCE-7E7A5E2B58C3

Q37091636-3718D85A-3A00-423B-B926-23C5A10085C9

Q37091636-9498B077-6ADD-48C8-AA50-23148418451D

Q37091636-B03EE16C-B42E-48B3-AF3E-CAA27043D7E8

Q37091636-D3B565A4-6B68-4F86-A741-5F4F615B7EDE

Q37091636-D7502E7B-6157-40BC-B0EF-6311DFA90E2F

Q37091636-F414403D-959D-4A86-AE80-7919102F06B3

P2860

Q37091636-10F777A0-4B9A-4F75-A97C-8DFC91A6FCA9

Q37091636-21DFD712-0673-4B53-847E-0E15427146DD

Q37091636-2C6B5D8A-1E71-454B-A109-38F0F7FF1F63

Q37091636-2F16ACC6-A16A-4090-9403-8B88E7E2D860

Q37091636-30451ADE-F2BD-4028-8651-6F612FCDE3AC

Q37091636-35849F56-A7B1-44EC-8CAB-E3AB9CABBF61

Q37091636-42C2B647-F727-47D0-A5D6-5B88481AD6E0

Q37091636-55C6ABF0-7056-4984-A7FB-4F133E64596E

Q37091636-5C35D530-C8E4-4548-8B5B-DF65AACD08FA

Q37091636-63D6FD78-C0D1-4E58-AC4C-AABE5F20A3BE

P304

Q37091636-4CA4751B-D501-47D4-B04C-1966B2D83D09

P31

Q37091636-3F090DE7-5310-4DED-B97B-EBAC2E0F82C7

P356

Q37091636-88F66DC8-4865-4BF4-A856-5EA5D80FC790

P433

Q37091636-A9BA227D-BBB0-414A-BB44-76386504E3D9

P478

Q37091636-14DBBC8F-2427-4A19-9FB5-5EAA47210ADA

P50

Q37091636-C6A06226-0BF8-45EA-98B1-DAC90F858075

P577

Q37091636-2EC92066-0590-417E-8BE5-0D78ECA6E4DA

P5875

Q37091636-8BE4EAF5-355B-4EA2-B7ED-5B75552090DF

P698

Q37091636-C3C407C3-48F9-4878-9607-100C342620FF

P921

Q37091636-C648C890-87E6-46C7-B421-3CDEF6C6BA89

P932

Q37091636-A36F32DA-B532-46CC-973B-A868C21EC35F

P356

P1433

Open forum infectious diseases

P1476

Retrospective Study of Cryptoc ...... in Immunocompromised Patients.

@en

P2093

Albert M Anderson

http://www.w3.org/2001/XMLSchema#string

Hashem Nasri

http://www.w3.org/2001/XMLSchema#string

Melhim Bou Alwan

http://www.w3.org/2001/XMLSchema#string

Minh L Nguyen

http://www.w3.org/2001/XMLSchema#string

Nadine Rouphael

http://www.w3.org/2001/XMLSchema#string

Paulina A Rebolledo

http://www.w3.org/2001/XMLSchema#string

Sarah Kabbani

http://www.w3.org/2001/XMLSchema#string

Yun F Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis

In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa

Correlation of fluconazole MICs with clinical outcome in cryptococcal infection

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.

Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis

Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.

Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.

P304

ofw076

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFW076

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Colleen S. Kraft

P577

2016-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

300085148

http://www.w3.org/2001/XMLSchema#string

P698

27419153

http://www.w3.org/2001/XMLSchema#string

P921

P932

4943554

http://www.w3.org/2001/XMLSchema#string